Biocryst To Present At 43Rd Annual J.P. Morgan Healthcare Conference

2025-01-07 07:16:30

(MENAFN- GlobeNewsWire - Nasdaq) RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET.

Link to the live Audio webcast and replay of the presentation may be accessed in the Investors & media section of BioCryst's website at .

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn .

BCRXW

Contact:
John Bluth
+1 919 859 7910
...

MENAFN07012025004107003653ID1109062908

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.